Hopp til hovedinnhold

Bipolar affektiv lidelse

Sist oppdatert: Sist revidert:
Sist revidert av:

Definisjon:
Manisk depressiv lidelse består av periode(r) med mani (type I) eller hypomani (type II), og periode(r) med depresjon, med gode perioder imellom
Forekomst:
Livstidsprevalens oppgis til ca. 1%
Symptomer:
Kan svinge mellom oppstemthet og nedstemthet og normale perioder
Funn:
En manisk pasient er ofte svært urolig, noen ganger aggressiv, og en normal samtale kan være vanskelig
Diagnostikk:
Strukturerte diagnostiske spørreskjemaer anbefales brukt når diagnosen skal stilles
Behandling:
En kombinasjon av medikamentelle og psykologiske tiltak
  • Nasjonal fagleg retningsline for utgreiing og behandling av bipolare lidingar. Helsedirektoratet 2012. [url]http://www.helsebiblioteket.no/retningslinjer/bipolare-lidingar/forord[/url]
  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.
  2. Nasjonal fagleg retningsline for utgreiing og behandling av bipolare lidingar. Helsedirektoratet 2012. www.helsebiblioteket.no  
  3. Marzani G, Price Neff A. Bipolar Disorders: Evaluation and Treatment. Am Fam Physician. 2021 Feb 15;103(4):227-239. PMID: 33587568. PubMed  
  4. Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387(10027):1561–1572. PMID: 26388529. PubMed  
  5. Ferrari AJ, Stockings E, Khoo J-P, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18(5):440–450.
  6. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorders in the world mental health survey intiative. Arch Gen Psychiatry 2011; 68: 241-51. PubMed  
  7. Morken G, Vaaler AE, Folden GE, Andreassen OA, Malt UF. Age at onset of first episode and time to treatment in in-patients with bipolar disorder. Br J Psychiatry 2009; 194: 559-60. British Journal of Psychiatry  
  8. Larsson S, Lorentzen S, Mork E, et al. Age at onset of bipolar disorder in a Norwegian catchment area sample. J Affect Disord 2010; 124: 174-7. PubMed  
  9. Moon J-H, Cho C-H, Son GH, et al. Advanced circadian phase in mania and delayed circadian phase in mixed mania and depression returned to normal after treatment of bipolar disorder. EBioMedicine. 2016;11:285–295. PMID: 27543154. PubMed  
  10. Berle JØ, Solberg DK, Spigset O. Behandling av bipolar lidelse under svangerskap og etter fødsel. Tidsskr Nor Legeforen 2011; 131: 126-9. Tidsskrift for Den norske legeforening  
  11. RELIS database 2016; spm.nr. 10439, RELIS Vest. Litium og graviditet. Dato for henvendelse: 14.01.2016. Nettsiden besøkt 06.05.19. legehandboka.no  
  12. Parikh SV, LeBlanc SR, Ovanessian MM. Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Can J Psychiatry 2010; 55: 136-43. PubMed  
  13. Fiedorowicz JG, Solomon DA, Endicott J, et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med 2009; 71: 598-606. PubMed  
  14. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010; 12: 1-9. PubMed  
  15. Cassidy F. Risk factors of attempted suicide in bipolar disorder. Suicide Life Threat Behav 2011; 41: 6-11. PubMed  
  16. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. PMID: 29536616. PubMed  
  17. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience 2009; 164: 331-43. PubMed  
  18. Sklar P, Ripke S, Scott LJ, et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nature genetics 2011; doi:10.1038/ng.943. DOI  
  19. Van Snellenberg JX, de Candia T. Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Arch Gen Psychiatry 2009; 66: 748-55. PubMed  
  20. Proudfoot J, Doran J, Manicavasagar V, Parker G. The precipitants of manic/hypomanic episodes in the context of bipolar disorder: a review. J Affect Disord. 2010.
  21. Frans EM, Sandin S, Reichenberg A, Lichtenstein P, Långström N, Hultman CM. Advancing paternal age and bipolar disorder. Arch Gen Psychiatry 2008; 65: 1034-40. PubMed  
  22. Joshi G, Wilens T. Comorbidity in pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am 2009; 18: 291-319. PubMed  
  23. PRAC recommends strengthening the restrictions on the use of valproate in women and Girls. European Medicines Agency. Press release 10.10.2014
  24. Berk M, Brnabic A, Dodd S, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 2011; 13: 87-98. PubMed  
  25. Hayes JF, Pitman A, Marston L et al. Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment A UK Population-Based Electronic Health Records Study. JAMA Psychiatry 2016; 73: 630-7. pmid:27167638 PubMed  
  26. Price AL, Marzani-Nissen GR. Bipolar disorders: A review. Am Fam Physician 2012; 85: 483-93. American Family Physician  
  27. Schoeyen HK, Kessler U, Andreassen OA, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry 2015; 172: 41-51. doi:10.1176/appi.ajp.2014.13111517 DOI  
  28. Helsedirektoratet. Nasjonal faglig retningslinje om bruk av elektronkonvulsiv behandling - ECT. IS-2629. Oslo: Helsedirektoratet 2017. helsedirektoratet.no  
  29. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013 Jun 27;346:f3646. doi:10.1136/bmj.f3646. DOI  
  30. Underhållsbehandling med nyare antipsykotiska läkemedel vid bipolär sjukdom. Statens beredning för medicinsk och social utvärdering (SBU). 2015 www.sbu.se  
  31. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-60. American Journal of Psychiatry  
  32. Suttajit S, Srisurapanont M, Maneeton N et al. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827-38. PubMed  
  33. Brown E, Dunner DL; McElroy SL, et al. Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2008; Dec 11: 1-10.
  34. Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission The STOP-PD II Randomized Clinical Trial. JAMA 2019; 322: 622-31. pmid:31429896 PubMed  
  35. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9. British Journal of Psychiatry  
  36. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-55. PubMed  
  37. Jochim J, Rifkin‐Zybutz RP, Geddes J, Cipriani A. Valproate for acute mania. Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No.: CD004052 Cochrane (DOI)  
  38. Cipriani A, Rendell J, Geddes Jr. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev 2006; 3: CD004362. Cochrane (DOI)  
  39. Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev 2003; (3): CD004040. Cochrane (DOI)  
  40. Rendell JM, Gijsman HJ, Bauer MS, Goodwin GM, Geddes GR. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006; (1): CD004043. Cochrane (DOI)  
  41. McKnight RF, de La Motte de Broöns de Vauvert SJ, et al. Lithium for acute mania. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD004048. DOI: 10.1002/14651858.CD004048.pub4. DOI  
  42. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64: 442-55. PubMed  
  43. Lam DH, Hayward P, Watkins ER, et al. Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry 2005; 162: 324-9. American Journal of Psychiatry  
  44. Castle D, White C, Chamberlain J, et al. Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. Br J Psychiatry 2010; 196: 383-8. British Journal of Psychiatry  
  45. Sullivan AE, Miklowitz DJ. Family functioning among adolescents with bipolar disorder. J Fam Psychol 2010; 24: 60-7. PubMed  
  46. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. Br J Psych 2008; 192: 5-11. PubMed  
  47. McGirr A, Vila-Rodriguez F, Cole J, et al. Efficacy of Active vs Sham Intermittent Theta Burst Transcranial Magnetic Stimulation for Patients With Bipolar Depression: A Randomized Clinical Trial. JAMA Netw Open. 2021. doi: 10.1001/jamanetworkopen.2021.0963 DOI  
  48. Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007; 11: 1-226. PubMed  
  49. Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. In: The Cochrane Library, Issue 3, 2003. The Cochrane Library  
  50. Hashimoto Y, Kotake K, Watanabe N, et al. Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2021 Sep 15;9:CD013575. doi: 10.1002/14651858.CD013575.pub2 DOI  
  51. Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev 2009; (1): CD004367. Cochrane (DOI)  
  52. Lähteenvuo M, Tanskanen A, Taipale H, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry 2018. pmid:29490359 PubMed  
  53. Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005; 62: 860-6. PubMed  
  54. Young AH, Hammond JM. Lithium in mood disorders:increasing evidence base, declining use?. Br J Psychiatry 2007; 191: 474-6. PubMed  
  55. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163-72. PubMed  
  56. National Institute for Health and Clinicial Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. CG38 2006.
  57. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999;318:149-153. British Medical Journal  
  58. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Women Ment Health 2005; 8: 77-87. PubMed  
  59. Tohen M, Hennen J, Zarate C, et al. Harvard first episodes project: predictors of recovery and relapse. Bipolar Disord 2002;4(suppl 1):135-136.
  60. Gitlin MJ, Swendsen J, Heller TL. et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635-40 American Journal of Psychiatry  
  61. Solberg DK, Refsum H. Oppfølging av pasienter som bruker litium. Tidsskr Nor Legeforen 2008; 128: 1410-2. PubMed  
  • Randolf Terje Vågen, medisinsk fagsjef, Divisjon psykisk helsevern, St. Olavs hospital
  • Ingard Løge, spesialist allmennmedisin, redaktør Norsk Elektronisk Legehåndbok

Tidligere fagmedarbeidere

  • Gunnar Morken, spesialist i psykiatri, førsteamanuensis, Psykiatrisk Institutt, Norges teknisk-naturvitenskapelige universitet, Trondheim
  • Olav Thorsen, spesialist allmennmedisin, Klubbgaten legesenter, Stavanger